The AstraZeneca vaccine (AZ vaccine), developed by the University of Oxford in the United Kingdom and British-Swedish multinational biopharmaceutical company AstraZeneca, is a collaborative effort.
The U.S. government said Monday (April 26) that it will share its own stockpile of tens of millions of doses of AstraZeneca’s (AZ) vaccine against commensal pneumonia (COVID-19) with other countries.
The Biden administration announced plans to share all the doses of AZ vaccine it has, as long as they pass safety reviews. Up to 60 million doses of the vaccine will be sent to other countries in the next few months.
The U.S. government sent millions of doses of vaccine to Mexico and Canada last month, but has still been keeping most of its stockpile in reserve.
The AZ vaccine is authorized for use in many countries, and U.S. drug regulators are considering granting emergency use authorization for the vaccine, but have not yet approved it.
White House press secretary Jen Psaki said at a press briefing that given that several vaccines are already authorized for use and available in large quantities in the U.S., including two vaccines requiring two doses and a single-dose vaccine, and that the U.K. AZ vaccine has not yet been authorized for use in the U.S., “in the coming months, we don’t need to use AstraZeneca in the fight against COVID in the fight.”
White House officials said the doses of the three vaccines approved by U.S. drug regulators are sufficient for Americans, although Johnson & Johnson’s vaccine was previously suspended for nearly two weeks due to concerns about symptoms of blood clots after vaccination.
As of April 26, nearly 29 percent of Americans had been fully vaccinated against the C.C.V. virus.
The CCP pneumonia vaccine (AZ vaccine), developed in collaboration with Oxford University in the United Kingdom and the British-Swedish multinational biopharmaceutical company AstraZeneca, has been suspended in some countries due to questions about its safety, and the vaccine has been renamed the Vaxzevria vaccine in the European Union, as dozens of people have died from post-vaccination blood clot symptoms following its mass rollout in the United Kingdom and other countries.
Recent Comments